Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
Sharana MahomedSharana MahomedDisebo PotloaneIzukanji T SikazweEdmund CapparelliIshana HarkooTanuja Narayansamy GengiahNonhlanhla Yende ZumaFarzana OsmanLeila MansoorDerseree ArcharyNqobile MyeniPrecious RadebeNatasha SamsunderNicole Doria RoseKevin CarltonLucio GamaRichard A KoupSandeep NarpalaLeonid SerebryannyyPenny MooreCarolyn WilliamsonBruno PozzettoCatherine HankinsLynn MorrisQuarraisha Abdool KarimSalim Abdool KarimPublished in: BMJ open (2023)
PACTR202112683307570.
Keyphrases
- placebo controlled
- phase iii
- phase ii
- double blind
- study protocol
- open label
- antiretroviral therapy
- hiv positive
- clinical trial
- hiv infected
- polycystic ovary syndrome
- hiv testing
- human immunodeficiency virus
- phase ii study
- hepatitis c virus
- hiv aids
- men who have sex with men
- randomized controlled trial
- pregnancy outcomes
- cervical cancer screening
- breast cancer risk
- south africa
- type diabetes
- pregnant women
- insulin resistance
- radiation therapy